Abstract

The metabolic syndrome, as a cluster of cardiovascular risk factors, may represent an important connection between cancer treatment and its common late effect of cardiovascular disease. Insight into the aetiology of the metabolic syndrome after cancer treatment might help to identify and treat cancer survivors with increased cardiovascular risk. In this review, we summarise current knowledge on the prevalence and pathophysiology of the metabolic syndrome in cancer survivors, and discuss current intervention strategies with an emphasis on new developments.

Original languageEnglish
Pages (from-to)193-203
Number of pages11
JournalLancet Oncology
Volume11
Issue number2
Publication statusPublished - Feb-2010

Keywords

  • ACUTE LYMPHOBLASTIC-LEUKEMIA
  • LONG-TERM SURVIVORS
  • GROWTH-HORMONE DEFICIENCY
  • HEMATOPOIETIC-CELL TRANSPLANTATION
  • DISSEMINATED TESTICULAR CANCER
  • CHILDHOOD BRAIN CANCER
  • BODY-MASS INDEX
  • ADULT SURVIVORS
  • BREAST-CANCER
  • CARDIOVASCULAR-DISEASE

Fingerprint

Dive into the research topics of 'The metabolic syndrome in cancer survivors'. Together they form a unique fingerprint.

Cite this